WHAT'S NEXT IN AI-ENABLED,
PRECISION CARDIAC CARE

 

 

Thank you for connecting with us at ACC.24

This year's ACC annual scientific session and expo was full of incredible energy and scientific discoveries. We were excited to see increased enthusiasm for the diagnostic benefits of using CCTA with AI analysis for earlier disease detection.

If you missed us at the conference, request your virtual demo of the Cleerly software platform to see firsthand how our technology can aid your workflow. We aim to remove the complexity of measuring atherosclerosis, stenosis, and ischemia. Our analysis can identify all three measure of cardiovascular health, and provide you with an actionable report to inform your treatment plan.

Below, see some highlights from the conference floor. We look forward to seeing you in 2025!

Request a Demo

 

Book a meeting with Cleerly

 

Schedule Now
 

Cleerly's ACC Events

Demonstrations daily // Saturday through Monday at Booth 2131

Poster presentations in Hall B4-5 and Moderated Poster Theaters 05, 07, and 08

Saturday, April 6
9:00AM - 4:45PM

Exhibit Hall open // Cleerly Booth 2131

9:45AM - 10:30AM
Sarah Bär
Hall B4-5

Prognostic Value of a Novel Artificial Intelligence-Guided CCTA-Derived Ischemia Algorithm Among Patients Undergoing Selective Hybrid CCTA/PET Perfusion Imaging for Suspected Coronary Artery Disease

9:45AM - 10:30AM
Leslie Cho
Hall B4-5

Characteristics and Outcomes for Statin-Intolerant Women Receiving Bempedoic Acid in the CLEAR Outcomes Trial

10:15AM - 10:25AM
Shant Malkasian
Moderated Poster Theater 07

Automated Detection of Adverse Low-Density Non-calcified Plaque Morphology

1:45PM - 2:30PM
Fatima Rodriguez
Hall B4-5

Characteristics and Outcomes for Statin-Intolerant Hispanic/Latinx Patients Receiving Bempedoic Acid: Results From a CLEAR Outcomes Pre-specified Sub-analysis

3:00PM - 4:00PM
Booth 2131

Meet Cleerly Leadership and Partners

Sunday, April 7
9:00AM - 4:45PM

Exhibit Hall open // Cleerly Booth 2131

11:15AM - 12:00PM
Nick Nurmohamed
Hall B4-5

Coronary Artery Disease Risk Factors, Symptoms, Physician Visits and Preventive Medical Therapy Prior to First Myocardial Infarction Among 4,657,412 Us Patients: Need for Improved Identification and Preventive Treatment

11:30AM - 11:40AM
Michael Holinstat
Moderated Poster Theater 05

Sotagliflozin, a First-in-Class SGLT1/2 Inhibitor, Inhibits Clotting Potential in the Vessel via Inhibition of Platelet Activation, Integrin Activation, and Aggregation in Human Platelets

1:15PM - 2:00PM
Samuel CR R. Sherratt
Hall B4-5

Sotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Modulated Expression of Glucose Transport and Inflammatory Proteins in Endothelial Cells Following Angiotensin II Stimulation

1:15PM - 2:00PM
Harold E. BaysWelcome
Hall B4-5

Bempedoic Acid and Cardiovascular Disease Outcomes in Patients With Obesity: A CLEAR Outcomes Subset Analysis

2:15PM - 3:00PM
Muhammad Faraz Anwaar
Hall B4-5

Relationship Between Differential Quantitative Coronary Plaque As Assessed on CCTA Across Various Measures of Obesity: Miami Heart Study at Baptist Health South Florida

3:15PM - 4:00PM
Juan Lopez
Hall B4-5

Return on Investment for a Novel Prevention Artificial Intelligence Guided CCTA Program

Monday, April 8
9:00AM - 2:00PM

Exhibit Hall open // Cleerly Booth 2131

8:40AM - 8:50AM
Sarah Bär
B213

Artificial Intelligence-Guided Automated Non-calcified Plaque Burden Quantification on Coronary Computed Tomography Angiography Predicts the Long-term Risk for Myocardial Infarction Among Patients With Suspected Coronary Artery Disease

9:45AM - 10:30AM
Anoop Titus
Hall B4-5

Association of Cardiovascular Risk Factors to Quantitative Coronary Plaque Characteristics: Miami Heart Study at Baptist Health South Florida

9:45AM - 10:30AM
Muhammad Faraz Anwaar
Hall B4-5

Variation of Coronary Atherosclerosis Across Spectrum of Increasing Lp(a) Using Quantitative CCTA Plaque Analysis: Miami Heart Study at Baptist Health South Florida

12:15PM - 12:25PM
Rahul Aggarwal
Moderated Poster Theater 08

Sotagliflozin Reduces Stroke Outcomes in Patients With Diabetes and Chronic Kidney Disease

 

Request a Demo

 

 

Book a meeting with Cleerly

 

Schedule Now
Patents

Cleerly continues to revolutionize heart attack and cardiovascular disease prevention and treatment everyday by inventing world-class technology. Cleerly invests significant time and resources in research and development towards this goal. To protect Cleerly’s research and development efforts, Cleerly has vigorously developed a robust intellectual property portfolio – all part of a strategy for protecting the innovations that make Cleerly an industry leader in cardiovascular disease prevention and treatment.

Cleerly’s products and services may be covered by or for use under one or more of U.S. Patent Nos. 11,922,627, 11,948,301, 12,023,190, 11,861,833, 11,967,078, 11,832,982, 11,690,586, 11,779,292, 11,730,437, 11,672,497, 11,737,718, 11,751,826, 11,660,058, 11,896,415, 11,751,830, 11,751,829, 11,302,001, 11,308,617, 11,238,587, 11,302,002, 11,321,840, 11,341,644, 11,244,451, 11,288,799, 11,276,170, 11,210,786, 11,232,564, 11,367,190, 11,315,247, 11,969,280, 11,094,060, 11,120,550, 11,120,549, 11,132,796, 11,094,061, 11,113,811, 11,501,436, 11,751,831, 11,642,092, 11,759,161, 11,317,883, 11,350,899, 11,766,230, 11,766,229, and 10,813,612, as well as other patents that are pending.

For additional information, please contact legal@cleerlyhealth.com.

Solutions
About

© 2024 Cleerly, Inc.